 <h1>Kyprolis Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>carfilzomib</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about carfilzomib. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Kyprolis.</p><h2>In Summary</h2><p><b>Common side effects of Kyprolis include:</b> asthenia, arthralgia, dyspnea, fever, thrombocytopenia, vomiting, and chills. <b>Other side effects include:</b> congestive heart failure, pulmonary edema, and reduced ejection fraction.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to carfilzomib: intravenous powder for solution</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, carfilzomib (the active ingredient contained in Kyprolis) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking carfilzomib:</p><p>
<i>More common</i>
</p><ul>
<li>Agitation</li>
<li>black, tarry stools</li>
<li>bleeding gums</li>
<li>bloating or swelling of the face, arms, hands, lower legs, or feet</li>
<li>blood in the urine or stools</li>
<li>blurred vision</li>
<li>burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings</li>
<li>chest pain or tightness</li>
<li>confusion</li>
<li>cough</li>
<li>decreased awareness or responsiveness</li>
<li>decreased urine output</li>
<li>depression</li>
<li>difficult or labored breathing</li>
<li>difficulty with moving</li>
<li>dizziness</li>
<li>drowsiness</li>
<li>fast, slow, or irregular heartbeat</li>
<li>headache</li>
<li>hoarseness</li>
<li>hostility</li>
<li>irritability</li>
<li>loss of consciousness</li>
<li>lower back or side pain</li>
<li>muscle spasms (tetany) or twitching</li>
<li>nausea</li>
<li>numbness or tingling in the hands, feet, or lips</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>pinpoint red spots on the skin</li>
<li>pounding in the ears</li>
<li>rapid weight gain</li>
<li>seizures</li>
<li>severe sleepiness</li>
<li>tingling of the hands or feet</li>
<li>trembling</li>
<li>trouble breathing</li>
<li>ulcers, sores, or white spots in the mouth</li>
<li>unsteadiness or awkwardness</li>
<li>unusual bleeding or bruising</li>
<li>unusual drowsiness, dullness, tiredness, weakness, or feeling of sluggishness</li>
<li>unusual weight gain or loss</li>
<li>vomiting</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Chills</li>
<li>continuing ringing, buzzing, or other unexplained noise in the ears</li>
<li>fever</li>
<li>hearing loss</li>
<li>muscle pain or cramps</li>
<li>painful blisters on the trunk of the body</li>
<li>weakness in the arms, hands, legs, or feet</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Dark urine</li>
<li>general feeling of discomfort or illness</li>
<li>light-colored stools</li>
<li>stomach pain, continuing</li>
<li>thickening of bronchial secretions</li>
<li>yellow eyes or skin</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Bleeding, blistering, burning, coldness, discoloration of skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site</li>
<li>blindness</li>
<li>dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position</li>
<li>fainting</li>
<li>joint pain, stiffness, or swelling</li>
<li>stomach pain</li>
<li>sweating</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of carfilzomib may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Back pain</li>
<li>body aches or pain</li>
<li>bone pain</li>
<li>constipation</li>
<li>diarrhea</li>
<li>dry mouth</li>
<li>ear congestion</li>
<li>flushed, dry skin</li>
<li>fruit-like breath odor</li>
<li>increased hunger</li>
<li>increased thirst</li>
<li>increased urination</li>
<li>loss of appetite</li>
<li>loss of voice</li>
<li>metallic taste</li>
<li>muscle weakness</li>
<li>pain in the arms or legs</li>
<li>runny nose</li>
<li>sneezing</li>
<li>sore throat</li>
<li>trouble sleeping</li>
<li>weight loss</li>
</ul><p>
<!-- end intravenous powder for solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to carfilzomib: intravenous powder for injection</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Anemia (47%), thrombocytopenia (36%), lymphopenia (24%), neutropenia (21%), leukopenia (14%)</p>
<p><b>Common</b> (1% to 10%): Deep vein thrombosis</p>
<p><b>Uncommon</b> (0.1% to 1%): Hemolytic uremic syndrome (HUS)</p>
<p><b>Rare</b> (less than 0.1%): Thrombotic thrombocytopenic purpura (TTP), thrombotic microangiopathy, hemorrhage<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Hypertension (14%)</p>
<p><b>Common</b> (1% to 10%): Cardiac failure (i.e., pulmonary edema, decreased ejection fraction), atrial fibrillation, tachycardia, palpitations, flushing</p>
<p><b>Uncommon</b> (0.1% to 1%): Cardiac arrest, myocardial infarction, myocardial ischemia, pericarditis, pericardial effusion</p>
<p><b>Rare</b> (less than 0.1%): Hypertensive crisis<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased aspartate aminotransferase (13%)</p>
<p><b>Common</b> (1% to 10%): Increased alanine aminotransferase, increased gamma-glutamyltransferase, hyperbilirubinemia</p>
<p><b>Uncommon</b> (0.1% to 1%): Hepatic failure, cholestasis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (28%), peripheral neuropathy (14%), dizziness (13%), hypoesthesia (12%), dizziness</p>
<p><b>Postmarketing reports</b>: Posterior reversible encephalopathy syndrome, paresthesia, hypoesthesia</p>
<p><b>Uncommon</b> (0.1% to 1%): Intracranial hemorrhage, cerebrovascular accident</p>
<p><b>Rare</b> (less than 0.1%): Posterior reversible encephalopathy syndrome (PRES)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (56%), pyrexia (30%), peripheral edema (24%), chills (16%), arthralgia (16%), asthenia (14%), pain (12%), infusion reaction</p>
<p><b>Common</b> (1% to 10%): Dysphonia</p>
<p><b>Uncommon</b> (0.1% to 1%): Multi-organ failure<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (35%), upper respiratory tract infection (28%), cough (26%), pneumonia (13%), nasopharyngitis</p>
<p><b>Common</b> (1% to 10%): Pulmonary hypertension, bronchitis, pulmonary embolism, pulmonary edema, epistaxis, rhinitis, wheezing</p>
<p><b>Uncommon</b> (0.1% to 1%): Lung infection</p>
<p><b>Rare</b> (less than 0.1%): Acute respiratory distress syndrome (ARDS), acute respiratory failure, pulmonary hemorrhage, interstitial lung disease, pneumonitis<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (45%), diarrhea (33%), vomiting (22%), constipation (21%), abdominal pain</p>
<p><b>Common</b> (1% to 10%): Oropharyngeal pain, dyspepsia, toothache</p>
<p><b>Rare</b> (less than 0.1%): GI hemorrhage, GI perforation<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Increased blood creatinine (24%)</p>
<p><b>Common</b> (1% to 10%): Acute renal failure, renal failure, renal impairment, decreased creatinine renal clearance<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypokalemia (14%), hypomagnesemia (14%), anorexia (12%), hyperglycemia (12%), hypercalcemia (11%), hypophosphatemia (11%), hyponatremia (10%)</p>
<p><b>Common</b> (1% to 10%): Dehydration, hyperkalemia, hypocalcemia, hyperuricemia, hypoalbuminemia</p>
<p><b>Uncommon</b> (0.1% to 1%): Tumor lysis syndrome<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Back pain (20%), extremity pain (13%), chest wall pain (11%), arthralgia, muscle spasms</p>
<p><b>Common</b> (1% to 10%): Musculoskeletal pain, musculoskeletal chest pain, bone pain, myalgia, muscular weakness<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Insomnia (17.9%)</p>
<p><b>Common</b> (1% to 10%): Anxiety<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Herpes zoster reactivation, sepsis, influenza, viral infection<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash, pruritus, erythema, hyperhidrosis<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Drug hypersensitivity<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Cataract, blurred vision</p>
<p><b>Frequency not reported</b>: Blindness and other adverse visual disturbances (due to PRES)<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. "Product Information. Kyprolis (carfilzomib)." Onyx Pharmaceuticals Inc, South San Francisco, CA. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>Is Kyprolis (carfilzomib) a chemotherapy drug and how does it work?</li>
<li>How is Kyprolis (carfilzomib) administered?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Kyprolis (carfilzomib)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>3 Reviews</li>
<li>Generic Availability</li>
<li>Drug class: proteasome inhibitors</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Kyprolis &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Multiple Myeloma</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to carfilzomib: intravenous powder for injection</i></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Anemia (47%), thrombocytopenia (36%), lymphopenia (24%), neutropenia (21%), leukopenia (14%)</p><p><b>Common</b> (1% to 10%): Deep vein thrombosis</p><p><b>Uncommon</b> (0.1% to 1%): Hemolytic uremic syndrome (HUS)</p><p><b>Rare</b> (less than 0.1%): Thrombotic thrombocytopenic purpura (TTP), thrombotic microangiopathy, hemorrhage<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Very common</b> (10% or more): Hypertension (14%)</p><p><b>Common</b> (1% to 10%): Cardiac failure (i.e., pulmonary edema, decreased ejection fraction), atrial fibrillation, tachycardia, palpitations, flushing</p><p><b>Uncommon</b> (0.1% to 1%): Cardiac arrest, myocardial infarction, myocardial ischemia, pericarditis, pericardial effusion</p><p><b>Rare</b> (less than 0.1%): Hypertensive crisis<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased aspartate aminotransferase (13%)</p><p><b>Common</b> (1% to 10%): Increased alanine aminotransferase, increased gamma-glutamyltransferase, hyperbilirubinemia</p><p><b>Uncommon</b> (0.1% to 1%): Hepatic failure, cholestasis<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (28%), peripheral neuropathy (14%), dizziness (13%), hypoesthesia (12%), dizziness</p><p><b>Postmarketing reports</b>: Posterior reversible encephalopathy syndrome, paresthesia, hypoesthesia</p><p><b>Uncommon</b> (0.1% to 1%): Intracranial hemorrhage, cerebrovascular accident</p><p><b>Rare</b> (less than 0.1%): Posterior reversible encephalopathy syndrome (PRES)<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (56%), pyrexia (30%), peripheral edema (24%), chills (16%), arthralgia (16%), asthenia (14%), pain (12%), infusion reaction</p><p><b>Common</b> (1% to 10%): Dysphonia</p><p><b>Uncommon</b> (0.1% to 1%): Multi-organ failure<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Dyspnea (35%), upper respiratory tract infection (28%), cough (26%), pneumonia (13%), nasopharyngitis</p><p><b>Common</b> (1% to 10%): Pulmonary hypertension, bronchitis, pulmonary embolism, pulmonary edema, epistaxis, rhinitis, wheezing</p><p><b>Uncommon</b> (0.1% to 1%): Lung infection</p><p><b>Rare</b> (less than 0.1%): Acute respiratory distress syndrome (ARDS), acute respiratory failure, pulmonary hemorrhage, interstitial lung disease, pneumonitis<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (45%), diarrhea (33%), vomiting (22%), constipation (21%), abdominal pain</p><p><b>Common</b> (1% to 10%): Oropharyngeal pain, dyspepsia, toothache</p><p><b>Rare</b> (less than 0.1%): GI hemorrhage, GI perforation<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Very common</b> (10% or more): Increased blood creatinine (24%)</p><p><b>Common</b> (1% to 10%): Acute renal failure, renal failure, renal impairment, decreased creatinine renal clearance<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypokalemia (14%), hypomagnesemia (14%), anorexia (12%), hyperglycemia (12%), hypercalcemia (11%), hypophosphatemia (11%), hyponatremia (10%)</p><p><b>Common</b> (1% to 10%): Dehydration, hyperkalemia, hypocalcemia, hyperuricemia, hypoalbuminemia</p><p><b>Uncommon</b> (0.1% to 1%): Tumor lysis syndrome<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Back pain (20%), extremity pain (13%), chest wall pain (11%), arthralgia, muscle spasms</p><p><b>Common</b> (1% to 10%): Musculoskeletal pain, musculoskeletal chest pain, bone pain, myalgia, muscular weakness<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Insomnia (17.9%)</p><p><b>Common</b> (1% to 10%): Anxiety<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Common</b> (1% to 10%): Herpes zoster reactivation, sepsis, influenza, viral infection<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash, pruritus, erythema, hyperhidrosis<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Drug hypersensitivity<sup>[Ref]</sup></p><h3>Ocular</h3><p><b>Common</b> (1% to 10%): Cataract, blurred vision</p><p><b>Frequency not reported</b>: Blindness and other adverse visual disturbances (due to PRES)<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. "Product Information. Kyprolis (carfilzomib)." Onyx Pharmaceuticals Inc, South San Francisco, CA. </p><p id="ref_3">3. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>Is Kyprolis (carfilzomib) a chemotherapy drug and how does it work?</li>
<li>How is Kyprolis (carfilzomib) administered?</li>
</ul><h2>More about Kyprolis (carfilzomib)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Español</li>
<li>3 Reviews</li>
<li>Generic Availability</li>
<li>Drug class: proteasome inhibitors</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Kyprolis &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Multiple Myeloma</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>